The burden of Covid 19 is increasing all over the world. Pidotimod, an Immunomodulator had been used in COPD patients to prevent the exacerbations of COPD and also in the prevention of Recurrent respiratory tract infections both in adults and children successfully. A recent study indicates that the number of COPD cases in India increased from 28.1 million in 1990 to 55.3 million in 2016 [1,2]. The correlation between immune dysfunction and chronic respiratory diseases such as COPD is well established. COPD is characterized by chronic inflammation of the airway which compromises innate as well as adaptive immune responses.

References

1. Deepak Talwar., et al. “A review on the role of Pidotimod in prevention of acute exacerbations of chronic obstructive pulmonary disease”. IP Indian Journal of Immunology and Respiratory Medicine1 (2019): 15-23.
2. India State-Level Disease Burden Initiative CRD Collaborators. “The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990–2016”.
3. , et al. “Pidotimod: the state of art”. Clinical and Molecular Allergy 13 (2015): 8.
4. Ashish Goyal. “Effectiveness, safety and cost analysis of add-on pidotimod in maintenance therapy for exacerbation of chronic obstructive pulmonary disease in adults”. IP Indian Journal of Immunology and Respiratory Medicine4 (2018): 203-209.

Citation

Citation: Pradyut Waghray. “Emerging Landscape in the Management of Covid 19. Role of Pidotimod".Acta Scientific Nutritional Health 4.8 (2020): 33-34.

Copyright

Copyright: © 2020 Pradyut Waghray. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.